Eligibility NCT00332709 Osteoporosis. Postmenopausal Inclusion Criteria Exclusion Criteria Estrogen- and progesterone-receptor status negative or unknown Yes
No
Completion of adjuvant tamoxifen therapy more than 6 months prior to study start Yes
No
Inflammatory Breast Carcinoma, Mastitis carcinomatosa Yes
No
Current/active dental problems including infection of the teeth or jawbone, dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures Yes
No
Recent (within 6 weeks) or planned dental or jaw surgery Yes
No
History of diseases with influence on bone metabolism such as Paget's disease and primary overactive parathyroid Yes
No
Prior or concomitant therapies: chemotherapy within the last 12 months, intravenous or oral bisphosphonates, systemic corticosteroids, anabolic steroids or growth hormones, Tibolone, parathyroid hormone, systemic sodium fluoride or any drugs known to affect the skeleton (such as calcitonin, mithramycin, or gallium nitrate) Yes
No
Patients with previous or concomitant cancers (not breast cancer) within the past 5 years EXCEPT adequately treated basal or squamous cell skin cancers or in situ cancer of the cervix. Patients with previous other cancer(s) must have been disease-free for at least 5 years. Yes
No
Patients currently receiving oral bisphosphonates must discontinue these at least 3 weeks prior to study start. Yes
No
